bluebird bio Inc (BLUE)
0.5044
+0.01
(+1.39%)
USD |
NASDAQ |
Sep 27, 16:00
0.5045
0.00 (0.00%)
After-Hours: 20:00
bluebird bio SG&A Expense (Annual): 165.51M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 165.51M |
December 31, 2022 | 140.33M |
December 31, 2021 | 209.97M |
December 31, 2020 | 239.95M |
December 31, 2019 | 235.84M |
December 31, 2018 | 174.13M |
December 31, 2017 | 93.55M |
Date | Value |
---|---|
December 31, 2016 | 65.12M |
December 31, 2015 | 46.21M |
December 31, 2014 | 23.23M |
December 31, 2013 | 14.13M |
December 31, 2012 | 6.846M |
December 31, 2011 | 4.615M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
140.33M
Minimum
2022
239.95M
Maximum
2020
198.32M
Average
209.97M
Median
2021
SG&A Expense (Annual) Benchmarks
Vertex Pharmaceuticals Inc | 1.137B |
Perspective Therapeutics Inc | 21.06M |
Protalix BioTherapeutics Inc | 14.96M |
Predictive Oncology Inc | 10.94M |
Spectral AI Inc | 20.86M |